TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The Justice Department says Michigan physician Jonathan Decker was convicted of peddling more than 2 million stimulant pills through the Done ADHD telehealth platform. Separately, the FDA cleared Motivista, a prescription digital therapeutic intended as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care, according to its developer. The source does not provide the conviction date, sentence, or details of the FDA’s clearance.
Michigan physician Jonathan Decker was convicted of peddling more than 2 million stimulant pills, including Adderall, through the Done ADHD telehealth platform, according to the U.S. Department of Justice. In a separate development, the FDA cleared Motivista as an adjunctive digital treatment for negative symptoms of schizophrenia in outpatient care, its developer, Click Therapeutics, said.
The Justice Department’s account, summarized in an October 7 psychiatry news report, identifies Decker as a physician from Michigan and says the pills included amphetamine-dextroamphetamine salts, the active ingredients in Adderall. The report describes the case as involving the Done ADHD platform, a telehealth service. It does not provide the charges, trial evidence, verdict date, or any sentence imposed.
Click Therapeutics said the FDA cleared Motivista as an adjunctive treatment for negative symptoms of schizophrenia for outpatient care. The report does not specify the product’s clearance pathway, its authorized instructions, or the evidence submitted to the agency. The description means it is intended to complement care, not that it replaces other treatment.
The same roundup covered other developments in mental health and psychiatry, including federal interest in public feedback on ibogaine drug development and a survey finding differing levels of public support for civil rights protections. It also noted that anxiety about AI is appearing in therapy sessions, citing the New York Times. Those items provide a snapshot of issues receiving attention; the report supplied no further data on the prevalence of AI-related anxiety.
Oversight and Digital Care
The conviction puts attention on prescribing practices in telehealth, particularly where controlled stimulants are involved. The Justice Department’s reported pill count indicates the scale of the case, but the available summary does not establish how the prescriptions were issued, what conduct prosecutors proved, or whether other people or companies face legal action. Those details matter to patients, clinicians, and regulators evaluating how remote prescribing is supervised.
The FDA clearance is a separate development in the use of digital products in psychiatric care. A therapeutic cleared for use alongside outpatient treatment could add a technology-based option for people with schizophrenia, but clearance alone does not tell readers how widely it will be offered, who may be eligible, or what outcomes patients can expect. Clinicians and patients will need the product’s official instructions and supporting evidence to understand its role.
Together, the two items show distinct questions facing mental health care: how to monitor prescribing delivered remotely and how to evaluate new digital tools. The report does not connect the conviction to Motivista or suggest that the developments are related beyond appearing in the same psychiatry roundup.
As an affiliate, we earn on qualifying purchases.
Separate Developments in Psychiatry
The report was published by MedPage Today on October 7, 2026, as a brief roundup of psychiatry news rather than a detailed account of either development. It attributes the conviction information to the Department of Justice and the Motivista announcement to Click Therapeutics. The underlying DOJ announcement and the company’s fuller clearance materials are not reproduced in the source material provided here.
The roundup also mentioned the FDA’s request for public feedback on ibogaine drug development, along with studies and reports on access to addiction treatment, depression, and other mental health issues. These topics are not evidence about the Decker case or Motivista. They help place the two headline items among several current policy, research, and care developments.
“The FDA cleared the prescription digital therapeutic Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care.”
— Click Therapeutics, as summarized by MedPage Today
As an affiliate, we earn on qualifying purchases.
Case and Product Details Missing
The available report does not state when Decker was convicted, which specific offenses were proven, whether he remains licensed, or what sentence he may face. It also does not explain the alleged prescribing arrangements or say whether the Done ADHD platform itself was accused of wrongdoing. The pill count and conviction are attributed to the Justice Department, but no court documents are included in the source material.
For Motivista, the report does not identify the date or legal basis of the FDA clearance, the precise patient population covered, or the clinical results behind the decision. It is also unclear when the product will be available and how it will be incorporated into outpatient care. The brief reference to AI-related anxiety gives no survey findings or clinical estimates, so its frequency and effects cannot be determined from this report.
As an affiliate, we earn on qualifying purchases.
Court and FDA Follow-up
Further information about the criminal case may come from court filings or additional statements by the Justice Department, including any sentencing details and the offenses underlying the verdict. The source material does not give a date for a next hearing or identify an appeal.
Click Therapeutics and the FDA may provide more information on Motivista’s clearance, authorized use, and evidence base. Until those details are available, the reported development is limited to clearance as an adjunctive outpatient treatment for negative symptoms of schizophrenia. No launch date or next regulatory milestone was listed.
digital therapeutic for schizophrenia
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who was convicted in the stimulant-pill case?
Jonathan Decker, MD, a physician from Michigan, was reported convicted, according to the Department of Justice as cited by MedPage Today.
How many pills were involved?
The report says the case involved more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts such as Adderall. It gives no further breakdown.
What is Motivista cleared to do?
Click Therapeutics said the FDA cleared it as a prescription digital therapeutic used alongside treatment for negative symptoms of schizophrenia in outpatient care. The source does not include detailed labeling or eligibility criteria.
Does the report say when Motivista will be available?
No. The roundup does not provide a launch date, pricing, or availability information.
What remains unknown about the doctor’s case?
The available account does not give the specific charges, conviction date, sentence, or any appeal information. It also does not say whether the Done ADHD platform was accused of wrongdoing.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
